dossier,pdf link,guideline,type,"changes in skin, fur, eyes, mucous membranes",changes in the respiratory system,changes in the circulatory system,changes in the nervous system,changes in somatomotor activity and behaviour patterns,tremors,convulsions,salivation,diarrhoea,lethargy,sleep,coma,body weight ,food and water consumption,ophtalmological examination,organ weight and organ/body weight,rectal temperature,biomonitoring (urine/faeces collection),other,peo-1,peo-2,peo-3,peo-1,peo-2,peo-3,lactate dehydrogenase,total protein or albumin,"cell counts and differentials for alveolar macrophages, lymphocytes, neutrophils and eosinophils","sodium ""Sodium""[Mesh]","potassium ""Potassium""[Mesh]","glucose ""Glucose""[Mesh]","total cholesterol","creatinine ""Creatinine""[Mesh]",blood urea nitrogen,"total protein ""Proteins""[Mesh]","albumin ""Albumins""[Mesh]","alanine aminotransferase ""D-Alanine Transaminase""[Mesh]","aspartate aminotransferase ""Aspartate Aminotransferases""[Mesh]","alkaline phosphatase ""Alkaline Phosphatase""[Mesh]",chloride,phosphorus,"calcium ""Calcium""[Mesh]",globulin,"total bilirubin ""Bilirubin""[Mesh]",triglycerides,clinical chemistry: other,appearance (colour and turbidity),volume,osmolarity or specific gravity,pH,"total protein ""Proteinuria""[Mesh]","glucose ""Glycosuria""[Mesh]","blood/blood cells ""Hematuria""[Mesh]","cholinesterase ""Cholinesterases""[Mesh]",lipids,"hormones ""Hormones""[Mesh]",acid/base balance,"methaemoglobin ""Methemoglobin""[Mesh]",heinz body,creatine kinase,bone marrow cytology ,troponins,lactate dehydrogenase,glutamate degydrogenase,"gamma glutamyl transpeptidase ""gamma-Glutamyltransferase""[Mesh]","haematocrit ""Hematocrit""[Mesh]","haemaglobin ""Hemoglobins""[Mesh] concentration",mean corpuscular haemoglobin concentration,mean corpuscular haemoglobin,mean corpuscular volume,"erythrocyte count ""Erythrocyte Count""[Mesh]","total leucocyte count ""Leukocytes""[Mesh]",differential leukocyte count,"platelet count ""Platelet Count""[Mesh]",reticulocytes,prothrombin time,clotting time,partial thromboplastin time,gross pathology: all gross lesion and masses,"gross pathology: liver ""Liver""[Mesh]","gross pathology: kidneys ""Kidney""[Mesh]","gross pathology: adrenals ""Adrenal Glands""[Mesh]",gross pathology: aorta,"gross pathology: bone marrow ""Bone Marrow""[Mesh] (and/or fresh aspirate)",gross pathology: testes,gross pathology: lacrimal glands(extraorbital),gross pathology: larynx (3 levels including the base of the epiglottis),"gross pathology: lungs ""Lung""[Mesh] ( typically left lung including main bronchi and pleura although right lung could be used)","gross pathology: lymph nodes ""Lymph Nodes""[Mesh] from the hilar region of the lung ( especially for poorly soluble particulate test chemical), more in depth examination and/or studies with immunological focus ( additional draining lymph nodes my be considered, e.g; those from the posterior mediastinal, internal jugular, parathymicn posterior cervical, auricular, and/or cervical/submandibular regions, lymph nodes (distal from the portal-of-entry),",gross pathology: mamary gland (male and female),gross pathology: muscle (thigh),gross pathology: nasopharyngeal tissues (at least 4 levels; 1 level to include the nasopharyngeal duct and the nasal associated lymphoid tissue (nalt),gross pathology: oesophagus,gross pathology: olfactory bulb,gross pathology: pancreas,gross pathology: parathyroids,"gross pathology: peripheral nerve ""Peripheral Nerves""[Mesh] (sciatic or tibial, preferably close to muscle)",gross pathology: pituitary,gross pathology: prostate,gross pathology: rectum,gross pathology: salivary glands,gross pathology: seminal vesicles,gross pathology: skin,"gross pathology: spinal cord ""Spinal Cord""[Mesh] (cervical, mid-thoracic, lumbar)",gross pathology: sternum,"gross pathology: stomach ""Stomach""[Mesh]",gross pathology: teeth,"gross pathology: thymus ""Thymus Gland""[Mesh]","gross pathology: thyroid ""Thyroid Gland""[Mesh]",gross pathology: tongue,"gross pathology: trachea ""Trachea""[Mesh]",gross pathology: ureter,gross pathology: urethra,"gross pathology: urinary bladder ""Urinary Bladder""[Mesh]",gross pathology: uterus,gross pathology: other target organ,gross pathology: vagina,gross pathology: epididymides,gross pathology: ovaries,gross pathology: femur and stifle joint,gross pathology: illeum,"gross pathology: spleen ""Spleen""[Mesh]","gross pathology: brain ""Brain""[Mesh] (including sections of cerebrum, cerebellum, and medulla/pons)",gross pathology: caecum,gross pathology: gallbladder,"gross pathology: heart ""Heart""[Mesh]",gross pathology: harderian glands,gross pathology: coagulation glands,gross pathology: jejunum,gross pathology: colon,gross pathology: duodenum,"gross pathology:eye (retina, optic nerve) and eyelids",histopathology: all gross lesion and masses,"histopathology: liver","histopathology: kidneys ""Kidney""[Mesh]","histopathology: adrenals ""Adrenal Glands""[Mesh]",histopathology: aorta,"histopathology: bone marrow ""Bone Marrow""[Mesh] (and/or fresh aspirate)",histopathology: testes,histopathology: lacrimal glands(extraorbital),histopathology: larynx (3 levels including the base of the epiglottis),"histopathology: lungs ""Lung""[Mesh] ( typically left lung including main bronchi and pleura although right lung could be used)","histopathology: lymph nodes ""Lymph Nodes""[Mesh] from the hilar region of the lung ( especially for poorly soluble particulate test chemical), more in depth examination and/or studies with immunological focus ( additional draining lymph nodes my be considered, e.g; those from the posterior mediastinal, internal jugular, parathymicn posterior cervical, auricular, and/or cervical/submandibular regions, lymph nodes (distal from the portal-of-entry),",histopathology: mamary gland (male and female),histopathology: muscle (thigh),histopathology: nasopharyngeal tissues (at least 4 levels; 1 level to include the nasopharyngeal duct and the nasal associated lymphoid tissue (nalt),histopathology: oesophagus,histopathology: olfactory bulb,histopathology: pancreas,histopathology: parathyroids,"histopathology: peripheral nerve ""Peripheral Nerves""[Mesh] (sciatic or tibial, preferably close to muscle)",histopathology: pituitary,histopathology: prostate,histopathology: rectum,histopathology: salivary glands,histopathology: seminal vesicles,histopathology: skin,"histopathology: spinal cord ""Spinal Cord""[Mesh] (cervical, mid-thoracic, lumbar)",histopathology: sternum,"histopathology: stomach ""Stomach""[Mesh]",histopathology:  teeth,"histopathology: thymus ""Thymus Gland""[Mesh]","histopathology: thyroid ""Thyroid Gland""[Mesh]",histopathology: tongue,"histopathology: trachea ""Trachea""[Mesh]",histopathology: ureter,histopathology: urethra,"histopathology: urinary bladder ""Urinary Bladder""[Mesh]",histopathology: uterus,histopathology: other target organ,histopathology: vagina,histopathology: epididymides,histopathology: ovaries,histopathology: femur and stifle joint,histopathology: illeum,"histopathology: spleen ""Spleen""[Mesh]","histopathology: brain ""Brain""[Mesh](including sections of cerebrum, cerebellum, and medulla/pons)",histopathology: caecum,histopathology: gallbladder,"histopathology: heart ""Heart""[Mesh]",histopathology: harderian glands,histopathology: coagulation glands,histopathology: jejunum,histopathology: colon,histopathology: duodenum,"histopathology: eye (retina, optic nerve) and eyelids",point of departure (pod) noael,description of pod ,target organ,critical effect,moribund or dead animals prior to study termination,mortality rate,discussion and results,conclusion,homogeneity and stability ,treatment prior to application,pH,"physical form (gas, vapour, solid aerosol, liquid aerosol, mixture)",particle count,size distribution,particle mass (mass median aerodynamic diameter mmad),geometric standard deviation associated with mmad,thermodynamic equivalent diameter for particles <100nm,count median diameter (cmd),geometric standard deviation associated with cmd,fraction of particles ,composition,purity (%),chemical batch nr,"additional characterisation (shape, surface area/specific surface area, surface chemistry, composition inclusing coating and surface modifications, surface charge, partcile solubility, and aggregation/agglomeration state",additional info,name,concentration (%),species/strain,source,"age at start of experiment (days, weeks, months, years)","age unit (day, week, month, year)","sex (female, male)",housing and feeding,weight,"weight unit (gram, kilogram)",n animals / group,"pre-test conditioning or screening (diet, quarantine, ophthalmologic examination and treatment for disease)",number of satellite group,nominal concentrations,analytical concentrations,dose level unit,"repeated administration scheme (5days/week, 7days/week)","nose-only, whole-body",volume,air flow rate,"air flow rate/exposure port ( noseonly), or animal load /chamber (whole-body)",source of air,pressure difference,stability of exposure and generation of atmosphere,chamber equilibrium,temperature,humidity,particle-size,analystical concentration,calibration of equipment,location of sensors,time to inhalation chamber equilibrium (t95),treatment of air supplied/extracted,number of volume changes per hour,duration of exposure (hour),degree of np agglomeration in the aerosol,duration of exposure (28 days),recovery period (day),year,GLP,SCCS comment to test,ref. in dossier,limit test ,range-finding study,interim group,control group ,klimisch score,additional information,own comments
phenoxyethanol,https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_195.pdf,OECD 412,in vivo,,,"on exposure days, the clinical examination was performed before, during and after exposure. body weight and food consumption were determined at the start of the exposure period, on day 7 and on day 13. at study termination, clinical-pathological examinations of the blood, gross necropsy, measurement of organ weights and histopathological examinations of selected organs were conducted (liver, kidneys, adrenals, testes, thymus, spleen, lung).low inhalation toxicity, decreased body weight gain (females only) and food consumption (males and females) were observed in animals exposed to 1000 mg/m³ of 2-phenoxyethanol. there were no treatment-related changes in clinical chemistry or haematology and no treatment related histopathological changes indicative of systemic toxicity. morphological changes such as minimal to slight degeneration/squamous metaplasia, hyperplasia/hypertrophy and minimal to slight inflammatory cell infiltrates were noted, indicating irritation potential in the nasal cavity, larynx and lung in mid- and high-dose animals. lung weights were increased in mid- and high-dose males. ",decreased body weight gain and food consumption,34.4 ,noaec  mg/m3/day,"nasal cavity, larynx and lung ",,no,,the noaec for local effects in upper airways and lung was determined to be 48.2mg/m3/day ,,decreased body weight gain (females only),decreased food consumption (males and females),,lung weights were increased in mid- and high-dose males. ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"as minimal to slight degeneration/squamous metaplasia, hyperplasia/hypertrophy and minimal to slight inflammatory cell infiltrates were noted, indicating irritation potential in larynx in mid- and high-dose animals.","as minimal to slight degeneration/squamous metaplasia, hyperplasia/hypertrophy and
minimal to slight inflammatory cell infiltrates were noted, indicating irritation potential in
the lung in mid- and high-dose animals.",,,,"as minimal to slight degeneration/squamous metaplasia, hyperplasia/hypertrophy and
minimal to slight inflammatory cell infiltrates were noted, indicating irritation potential in
the nasal cavity in mid- and high-dose animals.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,48.2,noaec mg/m3,,,no,,repeated inhalation exposure of rats to an aerosol containing up to 1000 mg/m³ of 2- phenoxyethanol for 6 hours per day for a total of 10 exposure days showed low inhalation toxicity. there were no treatment-related changes in clinical chemistry or haematology and no treatment related histopathological changes indicative of systemic toxicity,"the no-observed-adverse-effect concentration (noaec) for local effects in upper airways and lung was determined to be 48.2 mg/m3
.",,,,liquid aerosol,,,,,,,,,,> 99.9,41183068,,,air,,rat/wistar,,,,f & m,,,,10,,,"0, 40, 200, 1000","0, 48.2, 246, 1070",mg/m3,5 days/week,nose/head only,,,,,,,,,,,,,,,,,6,,14 d,,2007,yes,no data on lung lavage is available. the noaec derived should be multiplied with a factor of 5/7 in order to take into account the intermittent exposure (5 days a week). an adjusted noaec of 34.4 mg/m3/day may be used.,3,,,,a concurrent control group was exposed to conditioned air,2,,
decamethylcyclopentasiloxane,https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_174.pdf,OECD 412,in vivo,"no behavioural abnormalities or mortalities were seen during the study. no effects were seen on mortality, body weight or body weight gain, food intake, or clinical signs. urinalysis and biochemistry data indicated no changes of toxicological significance at termination of the treatment. however, a few minor changes with statistical significance were recorded in rats exposed to 1.5 and 2.29 mg/L (96 and 151/197 ppm). an increase (>10%) in absolute and relative liver weight with slight hepatocellular hypertrophy (females only), increased incidence of goblet cell proliferation in the nasal cavity (males and females), and minimal to slight interstitial inflammation in the lungs (males and females) were observed at the highest exposure concentration of 2.29/3.71 mg d5/L. i.e. 151/197 ppm. ",,,,,,,,,,,,,,,in rats exposed to 1.5 and 2.29 mg/L (96 and 151/197 ppm). an increase (>10%) in absolute and relative liver weight with slight hepatocellular hypertrophy (females only).  mean lung absolute weights and lung to brain weight ratios were significantly increased (<10%) in males and females at the highest dose.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,in rats exposed to 1.5 and 2.29 mg/L (96 and 151/197 ppm) there was slightly decreased mean corpuscular haemoglobin concentration. there was no apparent relationship between these effects and the treatment.,,in rats exposed to 1.5 and 2.29 mg/L (96 and 151/197 ppm) there was a slightly increased mean corpuscular volume. there was no apparent relationship between these effects and the treatment.,,in rats exposed to 1.5 and 2.29 mg/L (96 and 151/197 ppm) there was a  slightly increased leukocyte and lymphocyte counts in males. there was no apparent relationship between these effects and the treatment.,,,,,,,,an increase (>10%) in absolute and relative liver weight with slight hepatocellular hypertrophy (females only) were observed at the highest exposure concentration of 2.29/3.71 mg d5/L. i.e. 151/197 ppm. ,,,,,,,,minimal to slight interstitial inflammation in the lungs (males and females) was observed at the highest exposure concentration of 2.29/3.71 mg d5/L. i.e. 151/197 ppm. ,,,,,,"increased incidence of goblet cell proliferation in the nasal cavity (males and females), was observed at the highest exposure concentration of 2.29/3.71 mg d5/L. i.e. 151/197 ppm. ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,results indicate repeated inhalation exposure to d5 induced an early non-sustained increase in liver weight and an early burst of hepatocellular hyperplasia and centrilobular hypertrophy in female rats exposed to concentrations of 160 ppm. ,"according to physicochemical specifications, 160 ppm is the highest D5 exposure concentration that can be reliably generated and maintained as a vapor without interference by aerosol formation",,,vapor,,,,,,,,,,,,,test substance: d5,,,rat/fischer 344,,,,f & m,,,,10,,,"0, 0.45, 0.66, 1.34, 2.29/3.71 ",,"mg /l (0, 28, 42, 96, 151/197 ppm)",5 days/week for 4 weeks. animals were exposed to the highest exposure concentration of 2.29 mg/l (151 ppm) for days 1 to 6 while the exposure to 3.71 mg/l (197 ppm) was for the remaining duration of the study (week 2 to 4). ,nose only,,,,,,,,,,,,,,,,,6,,28 days,,,,,38,,,,,,"SCCS conclusion on general toxicity: the sccs has identified the liver as a potential target organ following repeated-dose oral exposure and liver, lungs and uterus as potential target organs following repeated-dose inhalation exposure. the effects observed on the liver were mainly an increase in liver weight. in the subchronic oral study (ref 45), this increase in liver weight was not accompanied by histopathological lesions and no biologically relevant alterations in enzymatic activities were observed. no liver effects were reported in the chronic inhalation toxicity/carcinogenicity study. therefore, the sccs followed the hed guidance document on how to interpret hepatocellular hypertrophy (2002) and concluded that these liver effects are not adverse. therefore the oral dose of 100 mg/kg bw may be considered as a noael. concerning exposure to d5 by inhalation, the inhaled concentration of 49 ppm was considered as a noaec.",